Discover Nkarta's groundbreaking cell therapy advancements, robust financials, and investment potential. Click here to read ...

Dividend investing appears to be a simple strategy on the surface, but in reality, it requires a much deeper analysis.

Bristol-Myers Squibb (NYSE:BMY) recently announced positive topline results from its Phase 3 trials for Sotyktu, generating ...

Bristol-Myers Squibb (NYSE:BMY) recently gained European Commission approval for Breyanzi, broadening treatment options for indolent non-Hodgkin lymphoma, which was a significant recent event. During ...

BREYANZI has significant market potential due to its innovative approach as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The growing prevalence of hematologic malignancies and ...

The European Commission (EC) has granted approval to Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy from Bristol Myers Squibb (NYSE: BMY) ...

Bristol Myers Squibb (BMS) has received approval from the European Commission (EC) for its CD19-directed CAR T cell therapy Breyanzi (lisocabtagene maraleucel) in follicular lymphoma (FL).

BREYANZI has significant market potential due to its innovative approach as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The growing prevalence of hematologic malignancies and ...

BREYANZI has significant market potential due to its innovative approach as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The growing prevalence of hematologic malignancies and ...

The European Commission approved Bristol Myers' Breyanzi for relapsed or refractory follicular lymphoma after two or more prior treatments. In a Phase 2 trial, Breyanzi showed a 97.1% overall ...

Bristol Myers Squibb gets European Commission approval to expand use of CAR T cell therapy, Breyanzi for relapsed or refractory follicular lymphoma: Princeton, New Jersey Monday, ...